The Microbiology of Coronaviruses
The end of 2019 marked the start of coronavirus disease (COVID-19) pandemic from China, which went on to envelope more than 190 countries and territories across the globe. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), from a group of betacoronaviruses, is responsible for COVID-19. The virulent factors include the presence of envelope and spike proteins having receptor bonding domains (RBD). Clinical manifestations can range from mild respiratory infections to fatal outcomes. The viability of virus ranges from 3 to 72 hours. Polymerase chain reaction (PCR) is the diagnostic test of choice in this pandemic situation. Due to the absence of specific antivirals and vaccine, adoption of preventive option can help to combat the specific life-threatening outcomes.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:70(Suppl 3) |
---|---|
Enthalten in: |
JPMA. The Journal of the Pakistan Medical Association - 70(Suppl 3)(2020), 5 vom: 09. Mai, Seite S44-S47 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Zafar, Humaira [VerfasserIn] |
---|
Links: |
---|
Themen: |
COVID-19 Vaccines |
---|
Anmerkungen: |
Date Completed 18.06.2020 Date Revised 18.12.2020 published: Print Citation Status MEDLINE |
---|
doi: |
10.5455/JPMA.08 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM310948126 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM310948126 | ||
003 | DE-627 | ||
005 | 20231225141208.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.5455/JPMA.08 |2 doi | |
028 | 5 | 2 | |a pubmed24n1036.xml |
035 | |a (DE-627)NLM310948126 | ||
035 | |a (NLM)32515374 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Zafar, Humaira |e verfasserin |4 aut | |
245 | 1 | 4 | |a The Microbiology of Coronaviruses |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 18.06.2020 | ||
500 | |a Date Revised 18.12.2020 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a The end of 2019 marked the start of coronavirus disease (COVID-19) pandemic from China, which went on to envelope more than 190 countries and territories across the globe. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), from a group of betacoronaviruses, is responsible for COVID-19. The virulent factors include the presence of envelope and spike proteins having receptor bonding domains (RBD). Clinical manifestations can range from mild respiratory infections to fatal outcomes. The viability of virus ranges from 3 to 72 hours. Polymerase chain reaction (PCR) is the diagnostic test of choice in this pandemic situation. Due to the absence of specific antivirals and vaccine, adoption of preventive option can help to combat the specific life-threatening outcomes | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Coronaviruses, SARS-CoV- 2, Respiratory Infections, Receptor Binding Domains, Angiotensin Converting Enzyme 2, Pandemic. | |
650 | 7 | |a COVID-19 Vaccines |2 NLM | |
650 | 7 | |a Viral Vaccines |2 NLM | |
773 | 0 | 8 | |i Enthalten in |t JPMA. The Journal of the Pakistan Medical Association |d 1977 |g 70(Suppl 3)(2020), 5 vom: 09. Mai, Seite S44-S47 |w (DE-627)NLM000033170 |x 0030-9982 |7 nnns |
773 | 1 | 8 | |g volume:70(Suppl 3) |g year:2020 |g number:5 |g day:09 |g month:05 |g pages:S44-S47 |
856 | 4 | 0 | |u http://dx.doi.org/10.5455/JPMA.08 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 70(Suppl 3) |j 2020 |e 5 |b 09 |c 05 |h S44-S47 |